Detalles de la búsqueda
1.
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.
Future Oncol
; 20(8): 447-458, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37882460
2.
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
J Med Econ
; 26(1): 1009-1018, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37505931
3.
Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
PLoS One
; 18(4): e0283479, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37043485
4.
Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study.
J Mark Access Health Policy
; 9(1): 1922163, 2021 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34122780
5.
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Ther Adv Respir Dis
; 13: 1753466618820186, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30803355
6.
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Clin Ther
; 39(10): 1986-2005.e5, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28967482
Resultados
1 -
6
de 6
1
Próxima >
>>